Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PH
Phio Pharmaceuticals Corp. Common Stock
PHIO
Volume
90.52K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PH
PHIO
PH
Phio Pharmaceuticals Corp. Common Stock
PHIO
News
·
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
Mkt Cap
$10.8M
Volume
90.52K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
GlobeNewswire Inc. · Aug 20, 2025
Phio Posts Wider Loss in Fiscal Q2
Phio Pharmaceuticals reported a Q2 2025 net loss of $2.2 million, with its lead candidate PH-762 showing promising early clinical results in cancer therapy. The company's INTASYL platform demonstrated positive safety and efficacy signals in gene-silencing cancer treatments.
The Motley Fool · Aug 14, 2025
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033
The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.
GlobeNewswire Inc. · Aug 23, 2024
Phio Pharmaceuticals Secures New Investor
--Fund invests in microcap equities --Fund invests in microcap equities
GlobeNewswire Inc. · May 17, 2024
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
-PH-762 is Phio’s lead product candidate
GlobeNewswire Inc. · May 15, 2024
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762
GlobeNewswire Inc. · May 9, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
-Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation -Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation
GlobeNewswire Inc. · Apr 30, 2024
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
-Injection in murine tumors shows the compound is well tolerated
GlobeNewswire Inc. · Apr 22, 2024
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological posters Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological posters
GlobeNewswire Inc. · Apr 16, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
GlobeNewswire Inc. · Apr 11, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PH
PHIO
Phio Pharmaceuticals Corp. Common Stock
Buy
Sell
Market
Limit
Soon
PHIO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PHIO yet.
Related Tickers
Earnings